Home pageATAI • NASDAQ
add
ATAI Life Sciences NV
2,25Â $
After Hours:(0,44%)+0,0100
2,26Â $
Data e ora chiusura: 26 giu, 18:29:10 GMT-4 · USD · NASDAQ · Disclaimer
Chiusura precedente
2,20Â $
Intervallo giornaliero
2,17Â $ - 2,25Â $
Intervallo annuale
1,03Â $ - 2,64Â $
Cap di mercato
451,69Â Mln USD
Volume medio
2,89Â Mln
Rapporto P/E
-
Dividendo/Prezzo
-
Borsa valori principale
NASDAQ
Notizie
Dati finanziari
Conto economico
Entrate
Utile netto
| (USD) | mar 2025info | Variazione Y/Y |
|---|---|---|
Entrate | 1,56 Mln | — |
Spese di gestione | 9,99Â Mln | -8,84% |
Utile netto | -26,43Â Mln | 1,06% |
Margine di profitto netto | -1699,74 | — |
Utili per azione | -0,15 | 11,76% |
EBITDA | -19,05Â Mln | 13,79% |
Aliquota fiscale effettiva | -0,49% | — |
Stato patrimoniale
Totale attivo
Totale passivo
| (USD) | mar 2025info | Variazione Y/Y |
|---|---|---|
Investimenti cash/breve termine | 98,20Â Mln | -7,57% |
Totale attivo | 195,78Â Mln | -27,25% |
Totale passivo | 43,51Â Mln | -5,13% |
Patrimonio netto totale | 152,27 Mln | — |
Azioni in circolazione | 200,34 Mln | — |
Prezzo/valore contabile | 2,89 | — |
Redditività dell'attivo | -27,13% | — |
Rendimento sul capitale | -29,67% | — |
Flusso di cassa
Flusso di cassa netto
| (USD) | mar 2025info | Variazione Y/Y |
|---|---|---|
Utile netto | -26,43Â Mln | 1,06% |
Liquidità di esercizio | -17,84 Mln | 20,96% |
Contanti da investimenti | -11,01Â Mln | -196,02% |
Contanti da finanziamenti | 59,60 Mln | — |
Flusso di cassa netto | 30,78Â Mln | 375,65% |
Flusso di cassa libero | -11,27Â Mln | 38,58% |
Informazioni
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine.
In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff.
Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways. Wikipedia
Fondazione
2018
Sito web
Dipendenti
54
